Key Takeaways Intellia stock has gained 29.8% in a month, outperforming the industry, sector and the market. Intellia advances late-stage gene therapy trials but faces safety concerns and future competition. Intellia aims to become a commercial-ready organization by the end of 2026.Intellia Therapeutics (NTLA) has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed the sector and the S&P 500 ind ...

Forward Looking Statements Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines Nasdaq: MGX May 2025 This presentation includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward looking statements, including statements regarding our cash runway, strategy and plans, industry environment, ...

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics (CRSP 6.43%) and Viking Therapeutics (VKTX 4.01%), two mid-cap biotech companies that have lagged broader equities over the trailing-12-month period.Even with these poor performances, however, there are solid reasons to consider investing in these stocks, especially at current levels. Read on to find out more. 1. CRIS ...

NTLA-2002 (Hereditary Angioedema - HAE) - NTLA-2002 aims to be the first to offer lifelong freedom from attacks and prophylaxis after a single dose for HAE, with a BLA submission planned in 2026[8] - Phase 2 study results showed 73% of patients were attack-free and off chronic prophylaxis after a single dose of NTLA-2002 at 16 weeks[37, 41] - The global market for HAE is projected to reach approximately $5 billion by 2028[8, 44] Nex-z (Transthyretin Amyloidosis - ATTR) - Nex-z aims to be the first to stabilize or reverse disease progression with a single dose for ATTR, with a BLA submission planned in 2028 for polyneuropathy[8] - Phase 1 data showed deep, rapid, and durable reductions in serum TTR, with an 89% reduction in ATTR-CM and a 90% reduction in ATTRv-PN at day 28[63] - The global market for ATTR is projected to reach approximately $12 billion by 2028[8, 86] Clinical Development and Milestones - Intellia expects three commercial launches starting in 2027[8] - The company plans to complete enrollment in the Phase 3 HAELO trial for NTLA-2002 in the second half of 2025 and the MAGNITUDE-2 trial for ATTRv-PN in 2026[2] - Intellia plans to enroll at least 550 patients in the Phase 3 MAGNITUDE trial for ATTR-CM in 2025 and complete enrollment in early 2027[2]

GLP-1 agonists, a type of drug used to treat diabetes and weight loss, could be the hottest growth story in healthcare today. Experts at Morgan Stanley estimate that the market could grow to a $150 billion opportunity over the next decade, representing a tenfold increase from its sales last year. Eli Lilly (LLY -0.40%) has captured approximately 35% of the GLP-1 market, alongside arch-rival Novo Nordisk, the current market leader at 65%. However, Eli Lilly could gain on, perhaps even surpass, its rival over ...

To select the list of the world's most influential businesses of the year, TIME editors requested nominations across sectors, surveyed its global network of contributors and correspondents around the world, and sought advice from outside experts. They evaluated each company on key factors, including impact, innovation, ambition, and success. The result is a diverse group of organizations shaping the future of business and society. About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Thera ...

An updated edition of the May 21, 2025, article.The promising field of genomics has undergone rapid evolution over the past decade. Genomics includes the study of a complete set of genes, their work process and way of interacting with each other and the environment. The primary focus is to evaluate all the genes of an organism rather than individual genes.This genetic information is being used to evaluate individual responses to drugs, leading to the development of targeted therapies. This, in turn, has pav ...

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- -Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025- -Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026- -Preclinical in vivo cardiovascular program CTX340™ advancing toward ...

Key Takeaways CRSP is the first to market a CRISPR/Cas9 therapy, with Casgevy approved for SCD and TDT in multiple regions CRSP's pipeline spans ex vivo and in vivo therapies, including early success with CTX310. NTLA focuses on late-stage in vivo programs but faces setbacks, including a liver safety concern with nex-z.CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the f ...

Creating transformative gene-based medicines for serious diseases Corporate Overview Q2 2025 CRISPR THERAPEUTICS – CONFIDENTIAL © 2025 CRISPR Therapeutics | 11 Forward-Looking Statements Statements contained in this presentation and other related materials regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ material ...